News Releases

Date Title
05/08/2013 Summary ToggleEnanta Pharmaceuticals Announces Financial Results for the Second Fiscal Quarter and Six Months Ended March 31, 2013
05/06/2013 Summary ToggleBreakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450
04/23/2013 Summary ToggleEnanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL
03/26/2013 Summary ToggleEnanta Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option
03/20/2013 Summary ToggleEnanta Pharmaceuticals Announces Pricing of Initial Public Offering
11/06/2012 Summary ToggleEnanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10/17/2012 Summary ToggleEnanta’s Lead Hepatitis C Compound ABT-450 Advances into a Phase 3 Clinical Trial through its Collaboration with Abbott
09/19/2012 Summary ToggleFierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
04/19/2012 Summary ToggleAbbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C
04/19/2012 Summary ToggleAbbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C